Eriodictyol exhibits potential for broad application in the treatment of hepatocellular carcinoma due to its ability to suppress hepatocellular carcinoma angiogenesis, motility, cell viability, and tumor growth by deactivating the NLRP3 inflammasome [113]. This evidence concerns the gene NLRP3 and hepatocellular carcinoma.